Gavi Headquarters Agreement

Gavi, the Vaccine Alliance, is a public-private partnership that helps vaccinate half of the world`s children against some of the world`s deadliest diseases. Since its inception in 2000, Gavi has helped immunize an entire generation – more than 888 million children – and prevent more than 15 million future deaths, helping to halve child mortality in 73 low-income countries. Gavi also plays a key role in improving global health security by supporting health systems and funding global stockpiles of ebola, cholera, meningitis and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation and reaching unvaccinated children still left behind by using innovative funds and the latest technologies – from drones to biometrics – to save millions more lives, prevent epidemics before they can spread and help countries on the path to self-sufficiency. To learn more, visit www.gavi.org and connect with us on Facebook and Twitter. The agreement was co-signed by Dr Julian Lob-Levyt, Director General of the GAVI Alliance, at a special ceremony in Bern. Following the negotiations and signing of the APA between Gavi and Moderna, which secures these cans for COVAX Facility participants, a long-term agreement will be signed between UNICEF and Moderna to enable the logistics of sourcing and delivering these cans to Gavi COVAX AMC participants. According to the headquarters agreement signed today on behalf of the Federal Council by Ambassador Paul Seger, Director of the Department of International Law, the Geneva-based GAVI Alliance enjoys the same privileges and immunities as other intergovernmental organisations in Switzerland. Geneva, 3 May 2021 – Gavi, the Vaccine Alliance, today announced the signing of an initial purchase agreement with Moderna for its COVID-19 vaccine (Moderna mRNA vaccine).

The agreement covers 500 million doses of the Moderna vaccine obtained on behalf of the COVAX facility. Initial delivery under the Agreement is for GAC-eligible participants, with the option to allocate and deliver to self-funded participants in the future. Geneva, 10 December 2021 – Gavi, the Vaccine Alliance, today announced that it has reached an agreement to access an additional 150 million doses of Moderna`s COVID-19 mRNA vaccine that will be made available to COVAX at its lowest progressive price in the world. This change to the existing Pre-Purchase Agreement (APA) between Gavi and Moderna means that a total of up to 650 million doses of the Moderna vaccine could be available to COVAX participants by 2021 and 2022. Evan O`Connell +41 79 682 18 95eoconnell@gavi.org „We are very pleased to announce this agreement with Moderna on additional volumes and faster access to cans for COVAX participants,” said Aurélia Nguyen, General Manager of the COVAX Facility OFFICE. „We continue to actively manage the COVAX portfolio to meet the needs of countries and remain adaptable in the face of this ever-changing pandemic: this agreement is another step in that direction. Gavi encourages all manufacturers to continue to prioritise a transparent, consistent and predictable supply of COVAX and to provide low-income countries with the long-term transparency needed to plan successful immunisation campaigns and increase coverage rates. As part of an urgent appeal to manufacturers to prioritise the supply of COVAX, Gavi and Moderna have also reached an agreement to anticipate the availability of 20 million doses for COVAX. These doses, which were originally scheduled to be published for COVAX in Q1 2022, will now be available in Q4 2021. „We are very pleased to sign this new agreement with Moderna, which will give participants in the COVAX facility access to another highly effective vaccine,” said Dr Seth Berkley, CEO of Gavi. „Portfolio expansion and diversification has always been a primary focus for COVAX and remain adaptable in the face of this ever-changing pandemic – including the growing threat of new variants. This agreement is another step in that direction.

„I am grateful to our COVAX partners for their tireless work and to the entire Moderna team for their collaboration in reaching this agreement. This is an important milestone as we work to ensure that people around the world have access to our COVID-19 vaccine,” said Stéphane Bancel, President and CEO of Moderna. „We recognize that many countries have limited resources to access COVID-19 vaccines. We support COVAX`s mission to ensure broad, affordable and equitable access to COVID-19 vaccines, and we remain committed to doing everything in our power to end this ongoing pandemic with our COVID-19 mRNA vaccine. The Moderna vaccine was recently added to the emergency room by WHO so that it can be delivered to participants at the COVAX facility. Supply through this APA is expected to begin in Q4 2021, with a total of 34 million doses available in 2021 and up to 466 million doses in 2022. The agreement also includes options for potentially accessing doses of a vaccine tailored to the variant in the future. .